Phio Pharmaceuticals Corp (PHIO)

Apr 23, 2025

Analysts Advise You To Maintain Your Position In Phio Pharmaceuticals Corp (NASDAQ: PHIO) - Stocksregister

Apr 23, 2025

Apr 23, 2025

Best Momentum Stocks to Buy for April 23rd - Nasdaq

Apr 23, 2025

Apr 23, 2025

Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX

Apr 23, 2025

Apr 23, 2025

Financial Snapshot: Analyzing Phio Pharmaceuticals Corp (PHIO)’s Key Ratio Metrics - DWinneX

Apr 23, 2025

Apr 23, 2025

Best Value Stocks to Buy for April 23rd - NewsBreak: Local News & Alerts

Apr 23, 2025

Apr 22, 2025

Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - knoxdaily.com

Apr 22, 2025

Apr 22, 2025

Phio Pharmaceuticals Corp (PHIO) deserves closer scrutiny - uspostnews.com

Apr 22, 2025

Apr 14, 2025

Investors’ Faith in Phio Pharmaceuticals Corp (PHIO) could reap rewards if they hold on for the long haul - uspostnews.com

Apr 14, 2025

Apr 13, 2025

Contrasting Phio Pharmaceuticals (NASDAQ:PHIO) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) - Defense World

Apr 13, 2025

Apr 11, 2025

Equities Analysts Offer Predictions for PHIO FY2025 Earnings - Defense World

Apr 11, 2025

Apr 10, 2025

PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose - MSN

Apr 10, 2025

Apr 10, 2025

3 Penny Stocks to Watch Now, 4/10/25 - TipRanks

Apr 10, 2025

Apr 09, 2025

Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled - MSN

Apr 09, 2025

Apr 09, 2025

Phio advances skin cancer treatment with successful trial By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

This Biotech Is Ripping Following Phase 1b Trial Announcement - The Globe and Mail

Apr 09, 2025

Apr 09, 2025

Crude Oil Down 4%; Neogen Shares Plunge After Q3 ResultsBloom Energy (NYSE:BE), Neogen (NASDAQ:NEOG) - Benzinga

Apr 09, 2025

Apr 09, 2025

Phio Pharmaceuticals Advances PH-762 Cancer Treatment in Phase 1 - GuruFocus

Apr 09, 2025

Apr 09, 2025

PHIO Advances PH-762 in Phase 1b Clinical Trial for Skin Cancers - GuruFocus

Apr 09, 2025

Apr 09, 2025

Is Phio’s Surge Sustainable? - timothysykes.com

Apr 09, 2025

Apr 09, 2025

Phio Pharmaceuticals Potential Skin Cancer Treatment Recommended for Dose Escalation - MarketScreener

Apr 09, 2025

Apr 09, 2025

Phio advances skin cancer treatment with successful trial - Investing.com

Apr 09, 2025

Apr 09, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Apr 09, 2025

Apr 09, 2025

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort - Newsfile

Apr 09, 2025

Apr 09, 2025

Breakthrough in Skin Cancer Trial: PH-762 Shows 100% Tumor Clearance as Study Advances - Stock Titan

Apr 09, 2025

Apr 09, 2025

Phio stock hits 52-week low at $0.99 amid sharp annual decline - Investing.com

Apr 09, 2025

Apr 09, 2025

Phio Pharmaceuticals’ (PHIO) Buy Rating Reaffirmed at HC Wainwright - Defense World

Apr 09, 2025

Apr 08, 2025

Phio stock hits 52-week low at $0.99 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 - Investing.com Australia

Apr 08, 2025

Apr 08, 2025

H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 By Investing.com - Investing.com India

Apr 08, 2025

Apr 03, 2025

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894 - Quantisnow

Apr 03, 2025

Apr 03, 2025

3 Reasons to Sell PLCE and 1 Stock to Buy Instead - The Globe and Mail

Apr 03, 2025

Apr 03, 2025

Groundbreaking Cancer Treatment Data: Phio's Dual Immunotherapy Candidates Show Promise - Stock Titan

Apr 03, 2025

Apr 01, 2025

Phio stock hits 52-week low at $1.22 amid sharp annual decline - Investing.com

Apr 01, 2025

Apr 01, 2025

Phio stock hits 52-week low at $1.22 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

Phio Pharmaceuticals Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 01, 2025

Apr 01, 2025

Virtu Financial LLC Makes New Investment in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) - Defense World

Apr 01, 2025

Mar 31, 2025

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update - TradingView

Mar 31, 2025

Mar 31, 2025

Phio's Cancer Drug Shows Complete Response as Company Slashes Losses by 33% - Stock Titan

Mar 31, 2025

Mar 31, 2025

Phio Pharmaceuticals Corp. (PHIO) reports earnings - qz.com

Mar 31, 2025

Mar 31, 2025

Phio Pharmaceuticals (PHIO) Expected to Announce Earnings on Monday - Defense World

Mar 31, 2025

Mar 19, 2025

PHIO PHARMACEUTICALS CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 19, 2025

Mar 12, 2025

PHIOPhio Pharmaceuticals Corp Latest Stock News & Market Updates - Stock Titan

Mar 12, 2025

Mar 10, 2025

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting - Quantisnow

Mar 10, 2025

Mar 10, 2025

Phio Reports 50% Complete Response Rate in Skin Cancer Trial - StockTitan

Mar 10, 2025

Mar 05, 2025

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study - Newsfile

Mar 05, 2025

Mar 04, 2025

PHIO stock touches 52-week low at $1.25 amid sharp annual decline - Investing.com Australia

Mar 04, 2025

Feb 28, 2025

Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated - MSN

Feb 28, 2025

Feb 26, 2025

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile

Feb 26, 2025